Please select the eligibility criteria that correspond to the clinical trial below.
Title: Improving Blood Pressure Management in Patients With Diabetes: SCRIP-HTN
Brief Summary: About 22% of Canadians have high blood pressure, or hypertension. However, studies have shown that only 1 out of 5 people with hypertension have their blood pressure controlled.

Diabetes is also an important risk factor for heart disease and stroke. About half of people with diabetes also have hypertension - a deadly combination. Studies have shown that only about 1 in 10 people with diabetes have their blood pressure controlled adequately - clearly something needs to be done to improve this.

Heart disease, stroke, hypertension, and diabetes are conditions that occur in the community, so we need to explore innovative solutions that will work in the community. Pharmacists are well-placed in the community to help identify people with diabetes and hypertension. This has worked very well in previous studies in patients with high cholesterol levels. Pharmacists and nurses have complementary skills which, when working as a team, may help identify and better manage hypertension in people with diabetes.

Our main objective is to test whether a community pharmacist and nurse team can improve blood pressure control in people with diabetes and hypertension.


Options:
A: Inclusion Criteria:

* individuals who fill a (incident or prevalent) prescription for inhaled corticosteroids (either monotherapy or in combination inhaler with long-acting beta-agonists) who have been diagnosed by a doctor as having asthma
* possessing a cell-phone with ability to send/receive text messages
* residing in British Columbia (BC), Canada and planning to reside in BC for the next 12 months
* registered with the medical services plan (MSP, the provincial insure of medically-required services) in the past 12 months, and planning to remain registered for the next 12 months
* designated pharmacy being the main drugstore for patient
* not participating in another interventional study
* consent to participate in the study.

Exclusion Criteria:

* Unable to communicate in English
* Under 14 years of age
B: Inclusion Criteria:

The following patients will be eligible for study participation:

* Patients with either type 1 or type 2 diabetes. Diabetes will be defined as those patients presently taking either oral hypoglycemic agents or insulin therapy (oral hypoglycemic agents to include all drugs in the drug classes of: alpha-glucosidase inhibitors, biguanides, meglitinides, sulfonylureas, thiazolidinediones and adjunctive therapy) taken for \>6 months to rule-out steroid-induced diabetes and gestational diabetes.

Exclusion Criteria:

Patients will be excluded from the study if they:

* Do not provide or are unable to provide written informed consent
* Refuse or are unlikely to attend follow-up visits for BP measurements
* Are institutionalized
* Are \<18 years of age
* Do not understand English
* Enrolled in other diabetes or hypertension trials

Subjects will be recruited whether or not they are receiving antihypertensive therapy.
C: Inclusion Criteria:

* Diagnosis of hypertension in the prior two years and on hypertension medications
* Access to the Internet and an e-mail address
* Ability to use a computer using the English language
* Medical care coverage which permits them to refill prescriptions at Group Health Cooperative pharmacies and a willingness to do so.
* Blood pressure on each of two screening visits averaging \> 90 mmHg diastolic or \> 140 mmHg systolic and \< 110 mmHg diastolic or \< 200 mmHg systolic

Exclusion Criteria:

* Diagnosed or history of diabetes, cardiovascular disease (ischemic heart disease, valvular heart disease, heart failure, arrhythmias, strokes or transient ischemic attacks, and peripheral vascular disease)
* Current treatment for cancer, on immunosuppressant or antiretroviral treatment.
* Surgery or hospitalization in the prior 3 months
* Pregnancy (or plans to become pregnant in the next 12 months)
* Plans to move out of the area or leave the health plan in the next 12 months.
* Upper arm circumference size \> 18 inches.
* Arrhythmia detected at screening visits
D: Inclusion Criteria:

* Must be 18 years old or above
* Capable of understanding and willing to provide voluntary informed consent before any protocol specific procedures are performed
* Capable of understanding and complying with the requirements of the protocol, and demonstrating a willingness to attend for all required visits.
* Able and willing to take inhaled medication.
* Have a valid prescription for use of a Seretide diskus inhaler or already using a Seretide diskus inhaler.
* Have a history of regular attendance in the pharmacy in which they are recruited which will be demonstrated by the subject having collected three prescriptions for any medication in that pharmacy in the six months preceeding their recruitment to the study.

Exclusion Criteria:

* Patient expressly reports that their physician has indicated that they will not be continuing to receive Seretide over the next 6 months

Answer: B